DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on November 22, 2005; DOI: 10.1124/dmd.105.007427


0090-9556/06/3402-288-295$20.00
DMD 34:288-295, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.007427v1
34/2/288    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goralski, K. B.
Right arrow Articles by Sinal, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goralski, K. B.
Right arrow Articles by Sinal, C. J.

BRAIN CYCLOSPORIN A LEVELS ARE DETERMINED BY ONTOGENIC REGULATION OF MDR1A EXPRESSION

Kerry B. Goralski, Philip D. Acott, Albert D. Fraser, David Worth, and Christopher J. Sinal

Department of Pharmacology (K.B.G., P.D.A., C.J.S.), Department of Pediatrics (K.B.G., P.D.A.), and Department of Pathology (A.D.F.), Dalhousie University, Halifax, Nova Scotia, Canada; IWK Health Centre, Halifax, Nova Scotia, Canada (K.B.G., P.D.A.); and Toxicology Laboratory, Capital Health, Queen Elizabeth II Sciences Centre, Halifax, Nova Scotia, Canada (A.D.F., D.W.)

Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies, CyA was administered (5 mg kg–1 i.p.) to 1-, 12-, and 19-day, and adult male and female mdr1a+/+ and mdr1a–/– mice. Peak blood CyA was lower in 1-, 12-, and 19-day-old (1000 ng ml–1) versus adult (1500 ng ml–1) mice but was similar in mdr1a+/+ and mdr1a–/– mice. Kidney mdr1a expression (measured by quantitative polymerase chain reaction) increased 2.5-fold in 19-day-old male and female mice and increased another 4-fold in adult females compared with adult males. Liver mdr1a expression increased 6-fold by day 12 compared with neonatal mice. Thereafter, maintenance of hepatic mdr1a expression in females and a reduction to neonatal levels in males was observed. Kidney/blood (8- to 9-fold) and liver/blood (12- to 15-fold) CyA levels were highest on days 12 and 19 and were not dependent on maturational changes in mdr1a mRNA levels. Adults had higher brain expression of mdr1a mRNA (3-fold), a corresponding 5-fold increase in immunodetectable P-glycoprotein, and 80% lower brain accumulation of CyA compared with 1-day-old mice. Conversely, in mdr1a-null mice, brain/blood CyA was similar in newborn and adult mice. A similar pattern was observed for the brain accumulation of the mdr1a substrate 3H-digoxin. We conclude that the risk for central nervous system drug toxicity could be higher in neonates or young children as a consequence of underdeveloped P-glycoprotein.


Address correspondence to: Dr. Christopher Sinal, Department of Pharmacology, Dalhousie University, Room 5E Sir Charles Tupper Building, 5850 College Street, Halifax, Nova Scotia, Canada B3H 1X5. E-mail: csinal{at}dal.ca




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
E. T. Morgan, K. B. Goralski, M. Piquette-Miller, K. W. Renton, G. R. Robertson, M. R. Chaluvadi, K. A. Charles, S. J. Clarke, M. Kacevska, C. Liddle, et al.
Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer
Drug Metab. Dispos., February 1, 2008; 36(2): 205 - 216.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Ose, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, T. Fujita, A. Yamamoto, and Y. Sugiyama
P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier
Drug Metab. Dispos., February 1, 2008; 36(2): 427 - 434.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. B. Goralski, T. C. McCarthy, E. A. Hanniman, B. A. Zabel, E. C. Butcher, S. D. Parlee, S. Muruganandan, and C. J. Sinal
Chemerin, a Novel Adipokine That Regulates Adipogenesis and Adipocyte Metabolism
J. Biol. Chem., September 21, 2007; 282(38): 28175 - 28188.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.